I completely disagree. They would have to sell over 100 million shares to fund a phase 3 trial. One of their biggest assets is their tax loss carryforward. This asset would be nullified by any change of control. A straight licensing deal that absorba the NOL is far more likely. It's still a tall order, but they may be able to get it done because the CEO is so well respected in cardiology circles.